Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Invesco Ltd.

Invesco Ltd. increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 10.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 536,391 shares of the company's stock after purchasing an additional 51,233 shares during the quarter. Invesco Ltd. owned 0.11% of Elanco Animal Health worth $6,496,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ELAN. Steward Partners Investment Advisory LLC boosted its stake in shares of Elanco Animal Health by 28.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock worth $124,000 after buying an additional 2,264 shares during the last quarter. DDD Partners LLC purchased a new stake in shares of Elanco Animal Health during the 4th quarter valued at about $5,974,000. Harbor Capital Advisors Inc. increased its position in shares of Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock valued at $13,135,000 after purchasing an additional 209,734 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Elanco Animal Health by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock worth $5,349,000 after purchasing an additional 45,795 shares during the period. Finally, Jones Financial Companies Lllp grew its position in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after buying an additional 2,059 shares during the period. Institutional investors own 97.48% of the company's stock.

Analyst Ratings Changes

ELAN has been the topic of several analyst reports. Stifel Nicolaus dropped their price target on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Morgan Stanley reduced their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Barclays reduced their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, Piper Sandler lowered their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $14.67.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, with a total value of $102,000.00. Following the purchase, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.89% of the stock is owned by company insiders.

Elanco Animal Health Price Performance

NYSE ELAN traded up $0.12 during trading hours on Thursday, reaching $9.60. The company's stock had a trading volume of 452,534 shares, compared to its average volume of 4,926,209. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The firm's 50-day moving average price is $9.94 and its 200-day moving average price is $11.56. The company has a market capitalization of $4.76 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.08 EPS. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.